Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $160,401 | $174,078 | $180,516 | $195,265 | $247,121 |
| Gross Profit | $56,917 | $56,525 | $55,682 | $61,464 | $64,612 |
| Operating Income | $8,153 | $7,935 | $8,414 | $8,536 | $9,417 |
| Net Income | $8,489 | $5,415 | $6,746 | $5,372 | $3,778 |
Over the five-year period, The Cigna Group’s revenue has shown a steady upward trend, growing from approximately 160.4 billion USD in 2020 to 247.1 billion USD in 2024. The most notable year-over-year revenue jump occurred between 2023 and 2024—a robust increase of around 26.6%—which stands out compared to the more modest gains in prior years (roughly 8–9% year-over-year increases, with a slight dip of roughly 3.7% in 2022). Gross profit has remained relatively stable in comparison, hovering between 55.7 and 64.6 billion USD, with slight declines in 2021 and 2022 and subsequent modest recoveries in 2023 and 2024. Operating income has also been fairly consistent, ranging from about 7.9 to 9.4 billion USD, suggesting that while the company grew its revenues considerably, its core operational profitability increased at a slower pace. In contrast, net income displays a much more volatile and declining pattern over the period. Starting at 8.5 billion USD in 2020, net income dropped significantly to 5.4 billion USD in 2021, recovered moderately to 6.7 billion USD in 2022, then fell again to 5.4 billion USD in 2023 and further to 3.8 billion USD in 2024. This trend indicates that despite healthy top-line growth, underlying factors—such as potentially rising non-operating expenses, higher tax liabilities, or increased interest costs—might be pressuring the bottom line. Overall, while the company appears to be expanding its revenue base robustly and maintaining operational control, the declining net income trend calls for a closer examination of cost structures and non-operating influences to assess long-term financial health and sustainability within the competitive healthcare industry.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.